MBX MBX Biosciences, Inc.
MBX Biosciences, Inc. (MBX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $268.2K.
Where they traded
Last open-market purchase: March 13, 2026 , by Hawryluk P. Kent .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Hoerter Steven L. | Chairman, President and CEO | Sell | 4,893 | $54.82 | $268.2K | 78,045 −5.9% of holding | |
| Azoulay Salomon | Chief Medical Officer | Sell | 373 | $53.96 | $20.1K | 14,026 −2.6% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.